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Background: Adult Growth Hormone Deficiency (AGHD) is a debilitating condition resulting from tumors, pituitary
surgery, radiation of the head, head injury, or hypothalamic-pituitary disease. This qualitative study was conducted
to better understand the multi-faceted impacts and treatment effects of GHD on adult patients’ daily lives.
Seven focus groups and four telephone interviews were conducted in three countries. Eligible AGHD patients were
age 22 or older who had started and stopped growth hormone treatment at least once as an adult. Transcripts
were analyzed thematically.
Results: Thirty-nine patients were interviewed; majority etiology was pituitary disease or tumor (62%). Thirty-four
patients (87%) were currently on growth hormone replacement therapy; therapy initiation mean age was 43 years.
Analysis identified five domains of disease impact: 1) Psychological Health - changed body or self-image and
negative emotional impacts; 2) Physical Health - problems with sleep/fatigue, sex drive, weight gain, hair, skin,
muscle/bone loss; 3) Cognition - concentration or memory trouble; 4) Energy Loss and its negative impacts
(productivity, exercise, chores, socialization, or motivation); and 5) Treatment Effect - treatment enhances quality of
life, enabling patients to increase effort (exercise, chores, or work improvements). Energy and sleep are improved.
Saturation of themes was reached after the sixth focus group. A conceptual model of GHD disease impacts was
developed.
Conclusions: Untreated AGHD has significant negative impacts for patients, which treatment often improves. It is
important for clinicians and researchers to understand these multiple impacts so that they can address them in
individualized treatment plans and incorporate them when assessing treatment outcomes.
Keywords: Growth hormone deficiency, Adults, Patient-reported outcome measure, Daily functioning, Well-beingBackground
Adult Growth Hormone Deficiency (AGHD) is a debili-
tating condition, associated with reduced muscle mass
and muscle strength, reduced bone mass or osteoporosis
and an increase in body fat [1,2]. Those with AGHD
include adults who were growth hormone deficient as
children and become adults with AGHD or adults
who become growth hormone deficient due to tumors,
pituitary surgery, radiation of the head, head injury or
hypothalamic-pituitary disease. AGHD leads to increased
morbidity and increased incidence of cardiovascular
events, a main cause of the increased mortality observed
in this population. A recent review of the epidemiology of
growth hormone deficiency (GHD) in both children and* Correspondence: mbrod@thebrodgroup.net
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unless otherwise stated.adults concluded that incidence and prevalence of GHD
are highly variable with findings from 1.2-33 per 100,000
persons per year to 4.6-40.6 persons, respectively [3]. It is
estimated that over 50 000 adults in the United States are
growth hormone deficient, with approximately 6 000 new
cases reported yearly (this figure includes children with
growth hormone deficiency that are transitioning to
adulthood) [4].
In addition to physiologic symptoms, GHD for adults
is also associated with impaired concentration and loss
of memory, dissatisfaction with body image, and de-
creased quality of life [5]. Important areas of impact for
AGHD include energy or vitality levels, mood, social iso-
lation and self-control [6,7]. Adults with AGHD may
also experience psychological impairments such as de-
pression, anxiety and social isolation [8-12].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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conditions such as AGHD where negative impacts are
numerous is essential to assist clinicians, policy makers,
payers and patients in understanding and deciding upon
treatment options. Unfortunately, currently available
measures are either not disease specific and have not
been developed for or validated within the population of
people with AGHD [13-15], do not have sufficient sup-
porting documentation [16], or use yes/no response
options that do not permit an assessment of degree of
impact or smaller changes in treatment efficacy [17].
This qualitative study was conducted as the first step in
the development process of a new PRO measure which
will address the shortcomings of previous measures by
assessing the full spectrum of impacts in the daily life of
patients, and capture both small as well as larger effects
of treatment on these impacts. Following FDA guidelines
in the development of PROs, expert interviews with cli-
nicians were conducted in combination with patient
focus group interviews and literature review. This data
was synthesized to support a conceptual model for the im-
pact and consequences of AGHD. The purpose of this
paper is to present the qualitative findings from this study.
Methods
Seven semi-structured (open ended questions with follow
up probes) focus groups and four telephone interviews
were conducted with adults diagnosed with AGHD. They
were held in three countries (Germany, United Kingdom,
and United States) and six cities (Frankfurt, London,
Munich, New York, Dallas, and San Francisco). Eligibility
for participation included: 1) 22 years of age or older;
2) diagnosed with AGHD of any etiology; 3) diagnosed by
a physician and able to provide proof of diagnosis with
GH (growth hormone) medication prescription for GH
medication, or letter from a physician stating diagnosis;
and 4) both on and off treatment for AGHD at least once
as an adult. The telephone interviews were conducted
with residents of New York City (1) and London (3) in
order to accommodate the participants’ inability to attend
the focus group discussion. Utilizing purposive sampling,
adults with AGHD were recruited through an inter-
national professional market research organization using
their proprietary database of potential study participants.
All participants gave their informed consent prior to their
inclusion in the study and received an honorarium for
their participation commensurate with their time and
effort. This project’s ethics approval was granted by Inde-
pendent Review Consulting, Inc. IRB (#09012-01).
The focus group and telephone interview guides were
designed to elicit the burden of illness and treatment im-
pacts of AGHD. The guides were comprised of open-
ended questions concerning perceived impacts of AGHD
on social, physical, and psychological aspects of life,productivity, treatment impacts and satisfaction, and
compliance. They were developed from preliminary re-
search through literature review, conducted using the
US National Library of Medicine’s PubMed database,
and interviews with six clinicians with AGHD expertise.
The focus group interviews were moderated by profes-
sional focus group leaders, and in the native language of
the participants. They were conducted in professional
market research focus group facilities. All of the English-
language telephone interviews and focus group interviews
were moderated by the first author, who is a licensed men-
tal health clinician and trained group moderator. Profes-
sional facilitators moderated the focus group interviews
conducted in Germany. To ensure consistency between
groups, all facilitators were trained by the first author. The
first author also observed all groups in person and listened
to respondents via simultaneous translation. The focus
group interviews were approximately two hours in length
and the telephone interviews were one hour in length.
The focus groups and telephone interviews were audio
taped, translated into English when conducted in a non-
English language, and transcribed verbatim. They were
analyzed (hand coded) and synthesized thematically using
a multi-step process: (1) individual interview statements
were examined; (2) statements were summarized; (3)
statements were grouped and coded into categories; and
(4) moderating variables (factors which may influence the
strength of the relationship between Growth Hormone
Deficiency (GHD) and impacts) were examined [18,19].
Concurrent with conducting the focus groups, six
clinical experts were identified by the first author as
established clinical experts in the field (endocrinologists
and nurse educators) who saw at minimum 100 AGHD
patients yearly. The clinicians were interviewed individu-
ally by telephone for approximately 1 hour each. These
clinicians identified key impacts of AGHD on patients:
energy levels, personal well-being, and body mass. Fur-
thermore, these clinicians acknowledged that existing
measures designed to assess impacts of AGHD were not
sensitive to the range and gradations of impact that
AGHD poses for patients.
Results
Sample characteristics
The study included a total of 39 respondents (see Table 1),
23 (59%) females and 16 (41%) males. Participants resided
in Germany (n = 14, 36%); the United Kingdom (n = 12,
31%), and the United States (n = 13, 33%). The average age
was 50.7 years (range 22–82). A majority of respondents
(n = 24, 62%) reported pituitary disease or pituitary tumor
as the cause of their GHD; however, for some the etiology
was unknown (n = 6, 15%). A majority (n = 34, 87%) was
taking medication at the time of the focus groups. The
average age for initiating treatment for GHD was 43 years
Table 1 Sample characteristics





(n = 14) (n = 12) (n = 13) (n = 39)
Gender; n (%)
Female 8 (57) 6 (50) 9 (69) 23 (59)
Male 6 (43) 6 (50) 4 (31) 16 (41)
Ethnicity; n (%)
Caucasian/White 3 (21) 11 (92) 9 (69) 23 (59)
Latino 0 (0) 0 (0) 3 (23) 3 (8)
Asian 1 (7) 1 (8) 0 (0) 2 (5)
Mixed 1 (7) 0 (0) 0 (0) 1 (3)
Other 0 (0) 0 (0) 1 (8) 1 (3)
Decline to report 9 (64) 0 (0) 0 (0) 9 (23)
Marital Status; n (%)
Married 8 (57) 7 (58) 7 (54) 22 (56)
Single 2 (14) 3 (25) 4 (31) 9 (23)
Partnered 2 (14) 1 (8) 2 (15) 5 (13)
Divorced 2 (14) 0 (0) 0 (0) 2 (5)
Widowed 0 (0) 1 (8) 0 (0) 1 (3)
Age; mean (range) 53.1 52.5 46.4 50.7





5 (36) 4 (33) 5 (38) 14 (36)
College degree 7 (50) 3 (25) 6 (46) 16 (41)
Graduate (or higher) 2 (14) 5 (42) 2 (15) 9 (23)
Employment status; n (%)
Not working for pay 7 (50) 5 (42) 4 (31) 16 (41)
Full time for pay 4 (29) 7 (58) 5 (38) 16 (41)
Part time for pay 2 (14) 0 (0) 4 (31) 6 (15)
Student 1 (7) 0 (0) 0 (0) 1 (3)
Age (years) at GHD
diagnosis; mean (range)
42.0 38.9 38.0 39.7
(8–63) (4–71) (10–61) (4–71)
Cause of AGHD; n (%)
Pituitary disease/tumor 12 (86) 8 (67) 4 (31) 24 (62)
Head trauma 0 (0) 0 (0) 2 (15) 2 (5)
Short stature 1 (7) 0 (0) 1 (8) 2 (5)
Hypopituitarism 0 (0) 1 (8) 1 (8) 2 (5)
Acromegaly; removal
of pituitary gland
0 (0) 1 (8) 1 (8) 2 (5)
Brain tumor 0 (0) 1 (8) 0 (0) 1 (3)
Unknown 1 (7) 1 (8) 4 (31) 6 (15)
Table 1 Sample characteristics (Continued)





(n = 14) (n = 12) (n = 13) (n = 39)
Currently on
GH treatment; n (%)
Yes 13 (93) 12 (100) 9 (69) 34 (87)
No 1 (7) 0 (0) 4 (31) 5 (13)
Age (years) first took GH
treatment; mean (range)
45.7a 44.3 38.9b 43.0c




5.0a 3.9 3.4 4.1
(1–15) (1–7) (0–7) (0–15)
Total AGHDAd score per
country; mean (range)e
7.9 9.8 11.5 9.7
(0–20) (0–22) (0–23) (0–23)
Number co-morbid
conditions; mean (range)
3.4 2.2 2.6 2.8
(1–7) (0–4) (0–8) (0–8)
aOne blank response.
bOne participant had never been on medication.
cTwo missing responses, n = 37.
dAGHDA: Quality of Life in Adult Growth Hormone Deficiency Assessment.
eScored 1 point for positive response, possible range 0–25.
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years (range 4–71). Sixteen (41%) were not working,
although education levels were distributed across all
categories.
The average number of self-reported comorbid condi-
tions per patient was 2.8. Conditions reported include:
endocrine disorders - including diabetes and thyroid
disorders (n = 29, 74%); metabolic conditions - including
elevated cholesterol (n = 16, 41%); arthritis, rheumatic
diseases, musculoskeletal conditions (n = 13, 33%); mental
health conditions - including depression and anxiety
(n = 11, 28%); and heart disease and/or cardiovascular
condition - including hypertension (n = 9, 23%). These
comorbid conditions were unsurprising, representative of
the health problems associated with AGHD in general.
Comparison across countries:
The mean age of respondents was similar across coun-
tries, as was the mean age of AGHD diagnosis. However,
there were relatively fewer respondents who were not
employed in the United States (n = 4, 31%), as compared
to Germany (n = 7, 50%) and the United Kingdom (n = 5,
42%). Respondents from the United Kingdom worked
full time more frequently (n = 7, 58%) than did those
from either Germany (n = 4, 29%) or the United States
(n = 5, 38%). The primary cause of AGHD in Germany
and the United Kingdom was pituitary disease/tumor
(Germany: n = 12, 86%; United Kingdom: n = 8, 67%).
However, in the United States, a range of causes existed
for respondents, including pituitary disease/tumor (n = 4,
31%), head trauma (n = 2, 15%), and unknown etiology
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the United Kingdom were taking GH treatment at the
time of the focus group interview (Germany: n = 13, 93%;
United Kingdom: n = 12, 100%). However, in the United
States only 9 (69%) respondents were taking GH. The
mean age the respondents initiated GH treatment was
similar across countries.
Themes generated by focus groups
The analysis identified five domains of impact: Psycho-
logical Health, Physical Health, Cognition, Energy Loss, and
Treatment Effects. Total saturation of themes was reached
after the sixth focus group. When considered by domain,
saturation was reached after the second focus group for
themes related to physical health and cognition, and by the
third focus group for themes related to daily life impacts
due to energy loss. Saturation was reached by the sixth
focus group for themes related to psychological health and
treatment effects.
Psychological health
Psychological health themes were the most dominant
themes discussed in these focus groups and interviews.
Respondents struggled with body and self-image and
reported a wide range of emotional impacts of AGHD, in-
cluding frustration, anxiety, anger or resentment, depres-
sion, irritability, and mood swings. Respondents reported
tension in relationships, and reduced social interaction as
a result of AGHD.
Very generally, respondents linked their troubles with
body image to the weight gain associated with AGHD,
whereas they often linked their troubles with self-image
to fatigue and low energy. Body image was discussed in
five focus groups and two telephone interviews, and self-
image was discussed in four focus groups and two tele-
phone interviews:
Body image:
Oh, horrible. Just, I just think I look horrible and I
feel really embarrassed when people see me who
haven’t seen me since my illness. If I bump into
people who I haven’t see for a while, I think they
must be looking at me and thinking, oh my God,
look how she’s let herself go. I do feel very
embarrassed at how I look. I never feel that
I look nice. (UK)
Yes, I somehow felt bad because I put on a lot of
weight and my father measures 1,70 m and weighs
100 kg and then suddenly I felt that I look very
much like him. I needed new clothes and
everything. It was really horrible to look like that
and I felt bad about it. (Germany)Self-image:
It was difficult. And I would complain to my wife,
not a lot of other people. She could tell that I was
not my same self. (USA)
You feel a bit of a failure that you’re not there
really to give the support that you always had
given. And also you hadn’t got the energy, I always
used to sit every night with them and do reading
and homework and things like that and I suppose
that went so yeah, I suppose it did affect me in
that way, I did feel a bit of a failure, I suppose in
that respect. (UK)
Depression was a common theme, and respondents
spoke about depression and AGHD in five focus groups
and three telephone interviews:
I was depressed all the time, and the doctor had
me on antidepressants for a good three years, and
then finally I managed to get him to agree to send
me back to the hospital. (UK)
Furthermore, respondents spoke about feeling easily
stressed and anxious:
Anxiety, like right now; there are times when I just
sit down and I can just feel like sometimes my
whole insides are just shaking and I have to take
these deep breaths. (USA)
Additional emotional impacts of AGHD included lack
of motivation, frustration, anger, irritability, and mood
swings. In combination, the psychological impacts re-
sulted in consequences for respondents’ relationships.
Many described social tensions with others, either as a
direct result of the impacts of AGHD or as something
that is difficult to talk about with friends, and these
themes were discussed in all seven focus groups and
three telephone interviews:
The latter years it ruined my marriage, and my
ex husband feels it’s what made him an alcoholic
because of the trauma of the stuff I went
through. (UK)
For example, on the weekend we're going to do
that – and then I feel bad and I'm tired and I
can't do that. And that creates problems. Of course,
he doesn’t tell me but then he is disappointed.
Again, we can't do that! You said you'll meet with
those friends and then you can't go there. And I try
to do it, really, I try but I feel bad. (Germany)
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of like a detriment that people don't know that you
have it because they see you and you look fine and you
look fine and then you feel like hell. So people look at
you like, "Well why are you fatigued?" or "Why do you
not feel like you can finish this project?" that's stressful.
It's like too much effort to even tell somebody what's
going on with you and explain it. "You're obviously
tall. You haven't suffered as a result of this." … It's not
physical to them. If it's not physical to them, it's not
valid to them. (USA)
In summary, respondents reported that the psycho-
logical impacts of AGHD were substantial, and extended
to how they perceive their bodies and themselves, as well
as how they are able to interact with family and friends.
Physical health
Respondents attributed a variety of physical health im-
pacts to AGHD, including sleep troubles, fatigue, loss of
sex drive, weight gain, hair and skin issues, muscle and
bone loss, and metabolism/digestion problems.
Of these, the most frequently cited were sleep troubles,
and fatigue. Respondents had difficulty falling asleep or
sleeping through the night, and were deeply fatigued dur-
ing the day. This resulted in additional daytime sleeping,
sometimes inappropriately (such as in the middle of a task
or conversation). These themes were noted in all seven
focus groups and three telephone interviews:
Sleep:
But it was the sleep really, well, my sleep patterns
were completely mixed up and just the tiredness all
the time. (UK)
I really have a bad sleep. First of all, I fall asleep
really late. In most cases, it's eleven or midnight
although I go to bed at nine knowing I have to go to
school the next morning and it takes forever to go to
sleep. And then I wake up again after two hours and
then I sleep again and then it continues like that.
(Germany)
Fatigue:
Oh, it’s really terrible. When I was at my lowest I
spent most of the day either sleeping or lying on the
living room floor with my feet on the couch. I was just
so tired I could not even get up and do anything.
(USA)
I was so tired. I didn’t take pleasure in anything.
(Germany)Respondents also reported loss of sex drive and desire
as an impact of AGHD. This theme was discussed in all
seven focus groups and two telephone interviews:
There is zero sex drive whatsoever. […]No desire. I can
look at my girlfriend and she’s a really adorable, cute,
sweet, beautiful person and I’m taken aback by her,
but there is not the impetus to go any further. It just
takes a lot of energy to cross that bridge. (USA)
The mood is different. Let me put it like this. I mean
as everybody says if you're tired, exhausted and worn
out, then, of course, you wouldn’t want any sexuality.
(Germany)
Additionally, respondents noted weight gain due to
AGHD as an impact that was occasionally misunder-
stood early in the diagnostic process. A few respondents
reported muscle mass and bone losses, metabolism/
digestion problems, and high cholesterol associated with
AGHD.
Cognition
Respondents reported that problems with memory and
an ability to focus or concentrate were associated with
AGHD. They also reported a general feeling of being
slower than others. These themes were discussed in all
seven focus groups and three telephone interviews:
Focus or concentration:
My concentration is quite bad. I used to love studying
and reading but now it, it’s a struggle for me just to
read like a paragraph in a magazine article, I just find
that I can’t concentrate long enough. (UK)
I start talking and it goes. That’s the thing: it’s hard to
hold onto something you know you’re about to say.
(USA)
Memory problems:
I feel, I forget things. People sometimes say do you
remember when we did this and that? And I say, yes
but I can't remember things from my past. And things
that people tell me now, I forget it in a few moments.
(Germany)
I very nearly lost my job because I was forgetting to do
things. When you know you’ve got a bad memory you
can write lists and you can set, particularly with
electronic calendars, and now I have things pop up
even to remind me to take my mobile home with me.
[…]But it was, that was, I was tired but I wasn’t sure
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things or whether I generally forgot things and now I
know that it’s I generally can’t remember things. (UK)
Respondents were bothered by their memory loss and
inability to focus, and described these impacts as substan-
tial in their lives, creating self-doubt in their abilities.
Energy loss
Energy loss was implicated in all of the major impacts to
daily life, including work, accomplishing home tasks
such as cleaning or cooking, exercise or sports, and
productivity. Respondents reported that low energy and
profound fatigue made it difficult to do the activities
they had accomplished easily prior to acquiring AGHD.
Many respondents reduced their hours of paid work or
changed their jobs to accommodate their loss of energy,
and some actually stopped working for pay because it
proved to be so difficult. Work losses were described in
every focus group and three telephone interviews:
Well, I used to work 40 hours a week. I can’t do that
anymore. I work maybe 15, 20 hours, you know,
because I’m always tired. I wake up tired and just
can’t do much. (USA)
I’ve had to give up my job. […] I did try to go back
to work last year for, I tried for about six months,
for fifteen hours a week, but it just didn’t work out,
I just hadn’t got the mental capacity or the physical
capacity really to do it, to take the stress, the speed
that you have to work and the accuracy, I just
couldn’t cope with it any more. (UK)
At home, respondents were unable to shop, cook, or
clean and often relinquished these tasks to others in the
household. If they were able to accomplish the task, it
was often through a great deal of effort and with breaks
from the task. These experiences were noted in six focus
groups and three telephone interviews:
I was in a very bad condition. After work, having
to do the household [chores]. And I didn’t feel like
doing anything. I was just tired and exhausted.
Really worn out. (Germany)
My mum would have to do the shopping for me,
she’d come round, around lunchtime, she’d perhaps
make me some lunch. I’d be asleep again when they
came home from school and work, so they’d be
waking me up when they came in. Nothing would
be prepared for them to eat. I wouldn’t have
achieved anything during the day, and just slept
most of the day. (UK)Several individuals recalled the time prior to AGHD
when they were active physically, participating in aerobic
activities such as biking or running for exercise and
playing sports. They were no longer able to do these
activities once they had acquired AGHD. This theme
was reported in five focus groups and three telephone
interviews:
[Compared with prior to being GHD] I would ride my
bike to work three or four times a week. It’s a four-mile
bike ride. That’s where I got my joy was walking and
riding my bike. I don’t do it anymore. I did yoga on a
regular basis. I didn’t do it [anymore]. (USA)
I love, for example, to do sports but I couldn’t do it
anymore. (Germany)
Generally, respondents felt that accomplishing any
task was challenging and they felt this as a loss of prod-
uctivity both at work and at home. Loss of productivity
was noted in six focus groups and four telephone
interviews:
I think that just feeling of not being able to do
anything, of just not being able to even walk to the end
of the street and back, not feeling like I could
participate in anything because of it. (UK)
I want to become productive again and I want to feel
better. (Germany)
I’d no energy to do anything at all, nothing
whatsoever. (UK)
In summary, energy loss due to AGHD sustained sub-
stantial impacts in daily life for these respondents, par-
ticularly in the areas of work and home life.
Treatment effects
Treatment with growth hormone positively impacted each
of these domains for these respondents. Respondents re-
ported that while on treatment, they lost weight and had
more energy and motivation for exercise. This, in turn,
improved their body image. They reported feeling better.
As a result, their self-image improved and they became
more socially active. Respondents stated that they had an
improved ability to cope with the anxieties and stresses of
life, and had fewer emotional swings or less depression. In
general, they were more motivated to return to the
activities that they had enjoyed previously, before they ac-
quired AGHD.
Physically, they slept better and felt less fatigue during
the day and experienced more energy. Some gained back
muscle tone and felt stronger, although the loss of sex
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two people. Hair growth returned for some respondents.
However, respondents reported that treatment did not
seem to improve problems with memory loss and focus
or concentration very substantially.
Importantly, with treatment, respondents were able to
resume their hobbies and exercise activities, and reported
that they were able to accomplish their household tasks
again. For those who were working, their work lives and
productivity had improved, and a few who had not been
working were considering a return to work because they
felt better and had more energy with treatment.
I was happy to get the product because I could more
actively participate in life again. And with much more
fun and pleasure and being able to participate in
sports exercises again. Many things I didn’t do in the
past. (Germany)
Also, with the growth hormone you could accomplish
certain things that you wouldn’t be able to do. You
can’t understand it because you have energy. (USA)
I feel good actually, very good at the minute,
previously I felt like I was, had a life of a 90 year old
lady and the energy levels of a 90 year old lady and
now I feel like I’m probably about 25, but I’m not. But,
yeah, no, I certainly have more energy and just, I just
feel good. (UK)Figure 1 Theoretical framework for impacts of AGHD.Theoretical framework of the impact of AGHD
From these data, a theoretical framework was developed
to illustrate the domains of AGHD impact, their con-
sequences, and factors that influenced individual expe-
rience. As shown in the model, the main domains the
GHD impacts for adults are Energy, Physical, Psycho-
logical, Cognitive and Treatment Burden. Additionally,
there are modifiers which can influence, either amelio-
rate or intensify, the degree that disease impacts the per-
son (see Figure 1).
Discussion
This study demonstrates that the burden of illness for
AGHD is substantial, with impacts to both psychological
and physical health related quality of life, including the
essential aspects of daily life such as work, home acti-
vities, and social relationships. As also shown in the
theoretical framework, these impacts are influenced by
multiple factors, some of which can be intervened with
while others cannot. It is important from both a clinical
and research perspective to understand and assess these
modifiers, especially the ones which can be influenced,
such as level of social support. Clinicians may then be
able to include recommendations for additional treat-
ments such as therapy or support groups when needed.
Further, researchers should be aware that these variables
may be important covariates when analyzing data from
studies including a measure of impact. Additionally,
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person’s daily life and functioning will allow clinicians to
incorporate discussion of these consequences with their
patients, which may lead to a more realistic under-
standing of their disease for both the clinician and the
patient. Of importance is that the direction of the in-
fluences between domains, consequences, and modifiers
is bi-directional as supported by our findings that treat-
ment for AGHD may alleviate many of the difficult im-
pacts associated with AGHD.
Importantly, as demonstrated with the data, there are
strong consequences for untreated AGHD, including over-
all life and work productivity; health; social stigma; part-
nership disruption such as difficulty or divorce; impacts
on employment; educational attainment and ultimately
financial status; social engagement; and life satisfaction.
This study contributes a strong international focus to
any discussion on the impacts of AGHD, with compel-
ling evidence that not only are the impacts substantial,
but relevant to people with AGHD in both the United
States and Europe. Respondents were in strong agree-
ment across countries about the impact of AGHD on
psychological, physical, cognitive, and energy aspects of
life. They expressed similar concerns about the effects of
these impacts on work, home, and social relationships,
suggesting that the major driver responsible for the im-
pacts of AGHD is the disease and not culturally specific
attitudes or beliefs.
A small sample size of 39 participants is a limitation of
this study. Recruitment was based on a database com-
prised of voluntary patients, and therefore, the study
sample may not be representative of all individuals with
AGHD. Additionally, allowing participants with AGHD
of any etiology and the lack of information regarding all
other concomitant hormonal dysfunctions creates obsta-
cles to a close-grained analysis delineated by hormonal
status and treatments for other hormonal dysfunctions.
The extent to which the impacts reported in these focus
groups was related to the loss of the pituitary gland and
related treatments instead of the GH deficiency itself
was not always clearly detailed in these focus groups, or
by these respondents. However, since many of the re-
spondents had multiple hormonal dysfunctions, the im-
pacts of these dysfunctions may have influenced some of
their responses.
Future research should continue to develop an under-
standing of impacts by etiology of AGHD, through both
qualitative and quantitative methodologies. As noted ear-
lier, the expert clinicians interviewed during this study
were dissatisfied with current measures available for as-
sessing impacts of AGHD on patients. Additionally, the
existing measure is not sensitive to change in symptom or
impacts, and other adapted measures have not been deve-
loped for or validated within the population of people withAGHD. The development of newer measures, which cap-
ture these multiple impacts and allows for a wider vari-
ation in severity response options, may help to address
this gap in assessment of AGHD as well as tailor treat-
ment plans for individual patient’s circumstances.
Conclusions
The respondent data from this study demonstrates how
important it is to be able to assess patient impacts fully,
and with an attention to the range and severity that
patients actually experience. A new measure with more
sensitivity than the existing measures would be helpful to
clinicians and regulatory agencies to assess the benefits of
treatment.
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